Novartis' Fabhalta改进了PNH患者的血红蛋白水平,成为唯一的口服治疗选择。 Novartis' Fabhalta improves hemoglobin levels in PNH patients, becoming the only oral treatment option.

新的研究结果显示,Novartis的口服药物Fabhalta改进了成人的血红蛋白水平,这些成人从其他治疗方法转而接受口服药物。 New study results show Novartis' oral drug Fabhalta improved hemoglobin levels in adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from other treatments. 第三阶段BAPPULSE-PNH研究发现,安全性和有效性始终如一,使Fabhalta成为PNH唯一的口服治疗选择。 The Phase IIIB APPULSE-PNH study found consistent safety and efficacy, making Fabhalta the only oral treatment option for PNH. PNH是一种罕见的血液疾病,引起贫血和其他严重症状。 PNH is a rare blood disorder causing anemia and other serious symptoms.